11:37 AM EST - Paladin Labs Inc. : and Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, announced today that they have entered into a license and supply agreement granting Paladin exclusive Canadian rights to market and sell Synera®, upon regulatory approval. Synera is a topical patch that combines lidocaine, tetracaine and heat, using Nuvo's proprietary "Controlled Heat Assisted Drug Delivery" (CHADD) technology. Paladin Labs Inc.
shares T.PLB are trading up $0.76 at $43.00.
